Thymosin Alpha-1 Fights Lung Cancer by Blocking Immune-Suppressor Cell Migration to Tumors
Thymosin alpha-1 inhibited NSCLC growth by promoting myeloid-derived suppressor cell apoptosis and blocking their migration to tumors through HIF-1α/VEGF suppression.
Quick Facts
What This Study Found
Thymosin alpha-1 promoted M-MDSC apoptosis by reducing Bcl-2/BAX ratio and inhibited MDSC migration to tumors by suppressing HIF-1α-mediated VEGF production in tumor cells.
Key Numbers
TA1 reduced M-MDSCs in patient blood and decreased MDSC accumulation and VEGF in mouse tumors.
How They Did This
Studies on peripheral blood M-MDSCs from NSCLC patients. Mouse subcutaneous xenograft tumor model. qRT-PCR, Western blotting, flow cytometry, and immunohistochemistry to examine mechanisms.
Why This Research Matters
Thymosin alpha-1 is already approved in many countries as an immune modulator. Understanding that it works against cancer partly by blocking MDSC recruitment provides rationale for combining it with immunotherapy drugs like checkpoint inhibitors.
The Bigger Picture
The tumor immune microenvironment is a major focus of cancer research. MDSCs are key contributors to immune evasion, and finding that an approved peptide drug can reduce their accumulation opens combination therapy possibilities with existing immunotherapies.
What This Study Doesn't Tell Us
Xenograft models don't fully recapitulate human tumor immunology. The specific doses and timing for optimal MDSC suppression in humans need determination. Clinical trial data for Tα1 as an anti-cancer agent in NSCLC is limited.
Questions This Raises
- ?Would combining thymosin alpha-1 with checkpoint inhibitors like anti-PD-1 enhance anti-tumor responses in NSCLC?
- ?Does Tα1's MDSC suppression extend to other solid tumor types?
- ?What is the optimal dosing schedule for Tα1 to maximize tumor microenvironment remodeling?
Trust & Context
- Key Stat:
- VEGF suppression thymosin alpha-1 reduces tumor VEGF production via HIF-1α, cutting off MDSC recruitment signals
- Evidence Grade:
- Combined human patient samples and animal model evidence with clear mechanistic pathway. Pre-clinical but uses an already-approved peptide drug.
- Study Age:
- Published in 2020. Thymosin alpha-1 in combination with immunotherapy continues to be explored in clinical settings.
- Original Title:
- Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 131, 110740 (2020)
- Authors:
- Yang, Zhenzhen, Guo, Jiacheng, Cui, Kang, Du, Yabing, Zhao, Huan, Zhu, Lili, Weng, Lanling, Tang, Wenxue, Guo, Jiancheng, Zhang, Tengfei, Shi, Xiaojing, Zong, Hong, Jin, Shuiling, Ma, Wang
- Database ID:
- RPEP-05219
Evidence Hierarchy
Frequently Asked Questions
What are myeloid-derived suppressor cells?
MDSCs are immune cells that tumors recruit to create a protective shield against the body's anti-cancer immune response. They suppress T cells and other immune attackers that would otherwise fight the cancer.
Is thymosin alpha-1 already used in medicine?
Yes, thymosin alpha-1 (brand name Zadaxin) is approved in over 30 countries as an immune booster, primarily used for hepatitis B and as an immune adjuvant. Its potential anti-cancer uses are being actively researched.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05219APA
Yang, Zhenzhen; Guo, Jiacheng; Cui, Kang; Du, Yabing; Zhao, Huan; Zhu, Lili; Weng, Lanling; Tang, Wenxue; Guo, Jiancheng; Zhang, Tengfei; Shi, Xiaojing; Zong, Hong; Jin, Shuiling; Ma, Wang. (2020). Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 131, 110740. https://doi.org/10.1016/j.biopha.2020.110740
MLA
Yang, Zhenzhen, et al. "Thymosin alpha-1 blocks the accumulation of myeloid suppressor cells in NSCLC by inhibiting VEGF production.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. https://doi.org/10.1016/j.biopha.2020.110740
RethinkPeptides
RethinkPeptides Research Database. "Thymosin alpha-1 blocks the accumulation of myeloid suppress..." RPEP-05219. Retrieved from https://rethinkpeptides.com/research/yang-2020-thymosin-alpha1-blocks-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.